Fluorine-18 Imaging for Non-Small Cell Lung Cancer
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- University of California, Davis · Other
This trial is looking for adults with non-small cell lung cancer that has spread to the brain. Participants will undergo imaging scans to assess their condition using a specific imaging agent.
You may be able to join if
- I am over 18 years old.
- I have been diagnosed with non-small cell lung cancer that has spread to the brain.
- My doctor thinks I will live at least 3 more months.
- I have tumor tissue available for testing.
- I can stay still for up to 60 minutes during scans.
- I can understand and sign a consent form.
- I plan to receive additional cancer treatment soon.
- I have had a PET/CT scan and an MRI of my brain within the last 21 days.
You may not be able to join if
- I am pregnant or breastfeeding.
- I am currently in prison.
- I have another type of cancer that could interfere with the study.
- I weigh more than 350 pounds.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.
Loading trial locations…